Free Trial
→ Elon says the ‘S’ word (From Paradigm Press) (Ad)tc pixel
OTCMKTS:INBP

Integrated BioPharma Q3 2026 Earnings Results & Report

Integrated BioPharma logo
$0.19 0.00 (0.00%)
As of 10/9/2026 11:40 AM Eastern

Integrated BioPharma reported Q3 2026 earnings on May 8, 2026. The company reported EPS of -$0.03, while revenue was $10.11 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Integrated BioPharma EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Integrated BioPharma Revenue Results

Actual Revenue
$10.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Integrated BioPharma Q3 2026 Earnings FAQ

Integrated BioPharma (OTCMKTS:INBP) reported earnings of -$0.03 per share for Q3 2026. The report was announced on Friday, May 8, 2026.

Integrated BioPharma reported revenue of $10.11 million for Q3 2026.

Integrated BioPharma Earnings Headlines

Integrated Biopharma’s Wholly-Owned Subsidiary, Manhattan Drug Company, Inc. Appoints Michael Richtmyer as Head of Operations
August 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/40718/integrated-biopharmas-wholly-owned-subsidiary-manhattan-drug-company-inc-appoints-michael-richtmyer-as-head-of-operations/
Integrated BioPharma, Inc.: Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
February 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67678611-integrated-biopharma-inc-integrated-biopharma-reports-results-for-its-quarter-ended-december-31-2025-200.htm
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
 |  Weiss Ratings (Ad)
Integrated BioPharma Holds 2025 Annual Stockholder Meeting
December 10, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/INBP/pressreleases/36420312/integrated-biopharma-holds-2025-annual-stockholder-meeting/
Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
December 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/02/3197639/0/en/rentschler-biopharma-and-coriolis-pharma-announce-strategic-collaboration-for-integrated-biopharma-solutions.html
INBP Integrated BioPharma, Inc.
June 15, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/INBP
See More Integrated BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integrated BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integrated BioPharma and other key companies, straight to your email.

About Integrated BioPharma

Integrated BioPharma (OTCMKTS:INBP), Inc. (OTCMKTS:INBP) is a healthcare products company engaged in the manufacture and distribution of vitamins, nutritional supplements, herbal products, and pharmaceutical products. Its activities are focused on products intended to support general health and wellness.

The company has historically served the U.S. market through a combination of proprietary products, contract manufacturing, and wholesale distribution activities. Its manufacturing capabilities have included a range of product formats, such as capsules, tablets, softgels, liquids, powders, creams, and lotions, depending on customer and product requirements.

Integrated BioPharma’s operations have included the development, production, and distribution of health-related consumer products for its own brands and other businesses. Publicly available information about its current leadership structure, product portfolio, and geographic reach is limited.

View Integrated BioPharma Profile
Earnings Tools